Skip to main content

Advertisement

ADVERTISEMENT

Interactive Features

Advertisement

Quiz
01/23/2024
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter,...
01/23/2024
Oncology
Quiz
12/05/2023
True or False: According to findings from a retrospective study, the use of radiotherapy (RT) as a bridging and salvage approach significantly improved in-field control outcomes, but increased toxicity among patients with relapsed/refractory...
True or False: According to findings from a retrospective study, the use of radiotherapy (RT) as a bridging and salvage approach significantly improved in-field control outcomes, but increased toxicity among patients with relapsed/refractory...
True or False: According to...
12/05/2023
Oncology

Advertisement

Quiz
12/01/2023
True or False: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy did not demonstrate feasibility among patients with mantle cell lymphoma (MCL) with secondary central nervous system (SCNS) involvement.
True or False: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy did not demonstrate feasibility among patients with mantle cell lymphoma (MCL) with secondary central nervous system (SCNS) involvement.
True or False: Anti-CD19...
12/01/2023
Oncology
Quiz
11/27/2023
True or False: Findings from the phase 2 CITADEL-205 trial indicated that PI3Kδ inhibitor parsaclisib demonstrated significant clinical benefits and a manageable safety profile among patients with R/R mantle cell lymphoma with no prior BTK...
True or False: Findings from the phase 2 CITADEL-205 trial indicated that PI3Kδ inhibitor parsaclisib demonstrated significant clinical benefits and a manageable safety profile among patients with R/R mantle cell lymphoma with no prior BTK...
True or False: Findings from the...
11/27/2023
Oncology
Quiz
11/21/2023
Results from a 5-year follow-up study found that gene polymorphisms, particularly the _____ single nucleotide polymorphism (SNP), demonstrated prognostic value for disease outcomes among patients with indolent non-Hodgkin lymphomas and mantle...
Results from a 5-year follow-up study found that gene polymorphisms, particularly the _____ single nucleotide polymorphism (SNP), demonstrated prognostic value for disease outcomes among patients with indolent non-Hodgkin lymphomas and mantle...
Results from a 5-year follow-up...
11/21/2023
Oncology

Advertisement

Quiz
11/14/2023
According to findings from an extended follow-up study on allogeneic stem cell transplantation (alloSCT) for R/R mantle cell lymphoma, which of the following statements is true?
According to findings from an extended follow-up study on allogeneic stem cell transplantation (alloSCT) for R/R mantle cell lymphoma, which of the following statements is true?
According to findings from an...
11/14/2023
Oncology

Advertisement